The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 Elite Edge Biotech Peptides: Legal and Regulatory Risks 503A Compounding Pharmacies Must Understand The hype around a new class of injectable drugs is in overdrive, but they have yet to be properly tested. Read the full story from Kishor Napier Raman at the link in bio., Photo: Oscar Colman Research Peptides for Sale Phoenix Pharmaceuticals, Inc.